Apotex Brimonidine/Timolol Ophthalmic Solution Class II Recall

The FDA announced a Class II recall of Brimonidine Tartrate/Timolol Maleate Ophthalmic Solution 0.2%/0.5% manufactured by Apotex Corp. The recall (Case No. D-0407-2026) was initiated due to lack of assurance of sterility. The affected product has NDC 60505-0589-1 and was distributed nationwide in the U.S.

Amerisource Meclizine Recall - Failed Tablet Specifications

Amerisource Health Services LLC, distributed by American Health Packaging, initiated a Class II recall of Meclizine Hydrochloride Tablets, USP 12.5 mg nationwide. The recall (D-0418-2026) was initiated due to failed tablet specifications affecting products with NDC codes 60687-775-65 and 60687-775-11. The recall is ongoing with no specific return deadline provided.

Octreotide Acetate 20mg Class II Sterility Recall

FDA classified a Class II recall for Teva Pharmaceuticals USA's Octreotide Acetate 20mg injectable suspension (NDC 0071-4185-25) due to lack of sterility assurance. The recall stems from quality system deficiencies identified at the contract manufacturer Pharmathen International S.A. in Greece during a routine FDA inspection. The affected product was distributed nationwide in the USA.

Levothyroxine 150 mcg, Class II recall

FDA announced a Class II recall of Levothyroxine Sodium Tablets USP 150 mcg (1000 tablet bottles) manufactured by Macleods Pharmaceuticals Ltd. for Macleods Pharma USA, Inc. The recall was initiated due to subpotent drug concerns. The recall is ongoing with nationwide distribution.

Octreotide Acetate 30mg Class II Recall - Sterility Concerns

FDA issued a Class II drug recall for Octreotide Acetate for Injectable Suspension 30mg single-dose vials distributed by Teva Pharmaceuticals USA, Inc. The recall was initiated due to lack of assurance of sterility stemming from quality system deficiencies identified during an FDA inspection at the contract manufacturer Pharmathen International S.A. in Greece. The recalled product was distributed nationwide in the United States.

Children's Ibuprofen Class II Recall - Foreign Substance

FDA has initiated Class II recall D-0390-2026 for Children's Ibuprofen Oral Suspension, USP (100 mg/5mL, 4 FL OZ bottle) manufactured by Strides Pharma Inc. The recall was issued due to confirmed presence of foreign substances, specifically gel-like masses and black particles detected in the product. The affected product was distributed nationwide and manufactured in India for Taro Pharmaceuticals U.S.A., Inc.

Boil Water Advisory Issued for City of McCune After Waterline Break

KDHE issued a boil water advisory for the City of McCune in Crawford County, Kansas on April 5, 2026 following a waterline break that caused loss of pressure in the distribution system. Residents are advised to boil water for one minute before drinking or cooking, and restaurants and food establishments should take precautions. The advisory will remain in effect until bacterial testing at a certified laboratory confirms the water is safe and KDHE issues a rescind order.

6th Circuit pauses CFPB open banking rule appeals pending rulemaking

6th Circuit pauses CFPB open banking rule appeals pending rulemaking

GENIUS Act State Regulatory Regime Substantially Similar Determination Framework

Treasury issued its first proposed rule under the GENIUS Act (enacted July 2025) implementing section 4(c), which establishes principles for determining whether state-level payment stablecoin regulatory regimes are "substantially similar" to the federal framework. The proposal permits issuers with up to $10 billion consolidated total outstanding issuance to opt for state regulation if approved by the Stablecoin Certification Review Committee. Comments are due June 2, 2026.

Delaware Stablecoin Licensing and Digital Asset Framework

Delaware senators introduced SB19 (Delaware Payment Stablecoins Act) and SB16 (Delaware Banking Modernization Act) on March 23, 2026, proposing a state licensing and regulatory framework for stablecoin issuers and digital asset service providers. The bills align with the federal GENIUS Act requirements, including 1:1 reserve backing, anti-money laundering obligations, and consumer disclosures.